http://www.3stocksonfire.com/trading/index.php?topic=3053.msg27260#msg27260
WOW!!! What a terrific presentation!!! Nice going NVAX! This is HUGE!!!!
CEO addressed many excellent news and development which includes patented processes, proprietary product licenses good til 2015, FDA approvals, $12 million partnership, clinically proven effective nano-particle technology estrogen delivery (Estrasorb), new products getting released in 2 weeks, AND of course, AVIAN VACCINE!!!
NVAX has patented process for mass producing large yield vaccine in a very short period of time (2 months instead of 6 months by using egg), excess production capacity to handle new product line (or new Avian vaccine), using proprietary nano-particle technology to develop a single dose Avian vaccine, increased R&D money to develop vaccine that if effective against the new European strain of H5N1 Avian virus, already have contact with High-Level government/Bush administration working on Avian contracts!!!!!!!!!!
Here's the rest of the highlights from the presentation at Bio Investor Forum 2005 in San Francisco:
- Remarkable day for NVAX - major partnership deal Estrasorb and tremendous market response - 10's of millions of volume activity. Yes, we already know that
- New management team and the transformation of NVAX
- New products (2 products to be released in 2 weeks)
- Avian vaccine and proprietary development
- Specialized contractor for NIH in the past and present
- Became CEO three months ago, worked with Merck for 10 years, developing vaccines! Oh my!
- Nano particle technology products
- Estrasorb distribution with King pharmaceutical was a mistake. New distribution is working.
- Licensing of Estrasorb product - patent good til 2015!!!
- Short term: Nano particle technology (small particle - transdermal) allows for quick penetration of skin entering the bloodstream and also moisturizes the skin to administer estrogen. Product stable at room temperature for 2 years. Patent til 2015. received FDA approval. $12.5 million deal with advance payment of $2 million. Already two licensed products
- Long term: Vaccine based on nano particle technology
- Avian flu development
- Have excess production capacity to bring new products to market - like Avian vaccine
- Working on Osteoporosis and allergy drugs formulation that are transdemal to allow quick absorption of medication right to the affected area. Oral medication takes a long time to reach the affected area.
- Nano particle technology can be applied to the oral delivery of medications.
- Working to achieve full potential of the nano technology
- Avian flu - NVAX has received tremendous amount of attention for development of vaccine and mass production
- H5N1 has been mutating the past several years. Asian strain is different from the European strain. The vaccine developed for Asian strain DOES NOT work for the European strain
- NVAX going after a particular vaccine instead of soluble protein.
- Has proprietary process
- NVAX is working on a vaccine using the current H5N1 strain of virus
- Using nano particle technology to develop a single dose Avian vaccine.
- Rapid sealable bags for vaccine development. Low cost, high volume, excellent yield
WOW. What can I say?
Dang, time to mortgage the house and buy every share of NVAX I can.
I am 100% invested in NVAX now. Unless I can find a better stock, I am staying!